Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- B-cell Non Hodgkin Lymphoma
- Follicular Lymphoma
- Indolent Non Hodgkin Lymphoma
- Marginal Zone Lymphoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then up to 5 years.
OUTLINE: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for up to 18 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for 30 days and then up to 5 years.
Tracking Information
- NCT #
- NCT03498612
- Collaborators
- National Cancer Institute (NCI)
- Merck Sharp & Dohme Corp.
- Investigators
- Principal Investigator: Ajay K. Gopal Fred Hutch/University of Washington Cancer Consortium
Get Well Soon